Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Price Target at $92.93

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $92.9333.

A number of equities research analysts recently commented on HSIC shares. UBS Group set a $94.00 price target on shares of Henry Schein and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Barrington Research set a $104.00 target price on Henry Schein in a research note on Wednesday, August 5th. Stifel Nicolaus set a $95.00 price target on Henry Schein in a research report on Wednesday, August 5th. Finally, BTIG Research increased their price target on Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently modified their holdings of HSIC. Parallel Advisors LLC raised its position in shares of Henry Schein by 12.7% in the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock valued at $97,000 after purchasing an additional 148 shares during the period. Mufg Securities Americas Inc. grew its stake in Henry Schein by 5.3% in the 2nd quarter. Mufg Securities Americas Inc. now owns 2,917 shares of the company’s stock valued at $244,000 after buying an additional 148 shares in the last quarter. New Mexico Educational Retirement Board grew its stake in Henry Schein by 4.2% in the 2nd quarter. New Mexico Educational Retirement Board now owns 4,950 shares of the company’s stock valued at $413,000 after buying an additional 200 shares in the last quarter. Jain Global LLC raised its holdings in Henry Schein by 2.0% during the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after acquiring an additional 207 shares during the period. Finally, Sanctuary Advisors LLC raised its holdings in Henry Schein by 4.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,856 shares of the company’s stock valued at $367,000 after acquiring an additional 209 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $89.81 on Thursday. The company has a market capitalization of $10.01 billion, a P/E ratio of 26.18, a price-to-earnings-growth ratio of 1.71 and a beta of 0.81. The company’s 50-day moving average is $87.58 and its 200 day moving average is $80.45. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $92.18.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities research analysts forecast that Henry Schein will post 5.36 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.